Howe & Rusling’s Avidity Biosciences RNAM Stock Holding History

Howe & Rusling’s Portfolio RNAM Stock Details RNAM Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q3	–	Sell	-40	Closed	-$1K	–	1175
2022 Q2	$1K	Buy	+40	New	+$595	﹤0.01%	990

Other funds holding RNAM

RTW Investments New York $10B AUM 135.35% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

CAC

Cowen and Company New York $2.97B AUM 105.26% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return

T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

APM

Avidity Partners Management Dallas, Texas $936M AUM 195% 1-Year Est. Return

Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return

Howe & Rusling's RNAM Position: Q3 2022 in Review

Howe & Rusling sold out of Avidity Biosciences (RNAM) in Q3 2022, closing a stake of 40 shares — an estimated $1K sold.

Howe & Rusling first reported a position in RNAM in Q2 2022 and held it in 1 quarter. The position peaked at $1K in Q2 2022. 127 funds tracked by Wall St. Rank hold RNAM as of Q3 2022.

Howe & Rusling reported no remaining Avidity Biosciences position as of Q3 2022 after selling out during the quarter.
Howe & Rusling sold 40 Avidity Biosciences shares in Q3 2022, an estimated $1K.
Howe & Rusling first reported a position in Avidity Biosciences in Q2 2022 and held it in 1 quarter.
Howe & Rusling's Avidity Biosciences position peaked at $1K in Q2 2022.
127 funds tracked by Wall St. Rank held Avidity Biosciences as of Q3 2022.

Based on Howe & Rusling's 13F filing for Q3 2022, filed 14 Nov 2022.